Phase
Condition
Neoplasms
Abdominal Cancer
Digestive System Neoplasms
Treatment
Somatostatin analog
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age ≥ 18 years;
Able to provide spoken and written informed consent for the trial;
Histopathological confirmed neuroendocrine tumor;
Fulfill the clinical criteria for PRRT;
At least one soft tissue lesion > 2 cm;
Aimed administered activity of 7400 MBq;
ECOG score (performance status) 0-2.
Exclusion
Exclusion Criteria:
Not possible to discontinue LA-SSA for 4-6 weeks;
Use of short-acting SSAs;
Pregnancy and lactating female patients;
Inability to comply to the study procedures;
Factors that might affect the biodistribution (for example, indication forfurosemide directly after PRRT infusion, limited fluid intake, any renal catheters,etc.).
Study Design
Study Description
Connect with a study center
Antoni van Leeuwenhoek
Amsterdam,
NetherlandsActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.